Pituitary Stalk Interruption Syndrome (PSIS) Cell Models for Research

Pituitary stalk interruption syndrome (PSIS) is a rare congenital disorder characterized by the triad of a thin or interrupted pituitary stalk, absent or ectopic posterior pituitary, and hypoplasia or aplasia of the anterior pituitary. The exact global incidence is unknown, but it is estimated to affect 1 in 10,000 to 1 in 50,000 live births, with a higher prevalence in males (male-to-female ratio approximately 2:1). According to the WHO, congenital hypopituitarism, including PSIS, contributes to significant neonatal and childhood morbidity, with mortality rates up to 5-10% in untreated severe cases due to adrenal crisis and hypoglycemia. Risk factors include perinatal events such as breech delivery, birth trauma, and hypoxia, as well as genetic mutations in genes like PROP1, POU1F1, HESX1, LHX3, and LHX4. Unlike malignant diseases, PSIS does not have a 5-year survival metric; however, long-term outcomes depend on early hormone replacement therapy, with normal life expectancy if adequately treated. NCI does not provide specific survival data for PSIS as it is not a cancer. The clinical impact includes growth failure, delayed puberty, and metabolic complications, underscoring the need for research into its molecular basis.

PSIS serves as an ideal model for studying pituitary development and congenital hypopituitarism due to its well-defined clinical phenotype and genetic heterogeneity. Key research questions include: how mutations in developmental transcription factors lead to pituitary stalk interruption; the role of signaling pathways like Wnt, Notch, and Hedgehog in pituitary organogenesis; and the interplay between genetic and environmental factors. Public datasets such as ClinVar, NCBI Gene, and GEO provide mutation and expression data. Subtypes based on genetic mutations (e.g., PROP1-related, HESX1-related) allow for targeted mechanistic studies. The rarity of PSIS makes it a valuable model for rare disease research, where gene-edited cell models can elucidate disease mechanisms and aid in drug discovery for hormone replacement therapies.

Although PSIS is not a carcinogenic disease, its pathogenesis involves developmental pathways that are often deregulated in cancer. Key pathways include:

• • Wnt/β-catenin signaling: Essential for pituitary progenitor proliferation and differentiation. Mutations in HESX1 can disrupt Wnt signaling, leading to pituitary hypoplasia.
• • Notch signaling: Regulates cell fate decisions in the pituitary. Dysregulation can cause progenitor cell depletion.
• • Hedgehog signaling: Critical for ventral diencephalon and pituitary development. SHH mutations are linked to holoprosencephaly and pituitary abnormalities.
• • Fibroblast growth factor (FGF) signaling: Involved in pituitary stalk formation. FGFR2 mutations can lead to stalk interruption.

These pathways are studied using gene-edited cell models to dissect stepwise contributions to PSIS.

Data from ClinVar, COSMIC, and NCBI Gene indicate several genes recurrently mutated in PSIS. The table below summarizes key alterations.

Note: Frequencies are approximate and based on cohort studies; COSMIC does not list PSIS as a cancer, so data are from ClinVar and literature.

Key signaling networks deregulated in PSIS include:

• • Wnt/β-catenin pathway:
• • HESX1 mutations impair β-catenin stabilization.
• • Reduced expression of Wnt target genes like LEF1 and AXIN2.
• • Notch pathway:
• • NOTCH2 and JAG1 mutations affect progenitor maintenance.
• • Downregulation leads to premature differentiation.
• • FGF/MAPK pathway:
• • FGFR2 mutations activate MAPK/ERK, disrupting stalk formation.
• • Cross-talk with BMP signaling.
• • PI3K/AKT pathway:
• • PTEN mutations (rare) can lead to overgrowth and pituitary dysfunction.
• • AKT1 mutations may alter cell survival.

These networks are interrogated using CRISPR knockout and knock-in models to identify therapeutic targets.

Several cell lines are used to study pituitary development and PSIS. Key lines include:

Organoids derived from patient iPSCs or embryonic stem cells can model pituitary development. Advantages include 3D structure, hormone secretion, and patient-specific genetics. However, PSIS organoids are rare and require gene editing to introduce mutations.

Note: These cell lines are commercially available from various sources.

Animal models for PSIS include:

• • Genetically engineered mouse models (GEMMs):
• • Prop1 knockout mice exhibit pituitary hypoplasia and hormone deficiencies.
• • Hesx1 knockout mice show forebrain and pituitary defects.
• • Pou1f1 mutant mice (Snell dwarf) have GH, PRL, TSH deficiencies.
• • Induced models:
• • Zebrafish with morpholino knockdown of hesx1 or prop1.
• • Rat models with perinatal hypoxia to mimic stalk interruption.
• • Patient-derived xenografts (PDX): Not applicable as PSIS is not neoplastic.

These models help study developmental timing and hormone replacement strategies.

CRISPR/Cas9 technology enables the creation of isogenic cell lines with specific PSIS-associated mutations. Examples include:

• • PROP1 knockout in GH3 cells to model loss of function and study differentiation blocks.
• • POU1F1 knock-in of missense mutations (e.g., R271W) in HEK293T cells to assess DNA binding and transcriptional activity.
• • HESX1 knockout in mouse embryonic stem cells to study forebrain and pituitary development.
• • LHX3 knockout in αT3-1 cells to evaluate gonadotroph differentiation.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, validated tools. These models are engineered using CRISPR and are available from commercial sources without naming specific companies. They enable precise interrogation of mutation effects and drug responses.

Gene-edited cell models are used to validate gene function in PSIS. For example:

• • Knockout of PROP1 in pituitary progenitor cells confirms its role in maintaining progenitor pool and differentiation.
• • Knock-in of HESX1 mutations (e.g., R160C) demonstrates impaired repression of target genes like LHX3.
• • CRISPR screens can identify synthetic lethal interactions with PROP1 mutations, revealing compensatory pathways.

These studies provide mechanistic insights and potential drug targets.

Isogenic pairs (wild-type vs. mutant) enable high-throughput drug screening. For PSIS, drugs that restore hormone production or promote pituitary cell proliferation can be tested. Examples:

• • Screening for small molecules that rescue PROP1-dependent differentiation.
• • Testing hormone replacement therapies in patient-derived cells.
• • Resistance modeling is less relevant as PSIS is not treated with chemotherapy, but drug resistance in hormone therapy can be studied.

Gene-edited cells provide a platform for personalized drug testing.

CRISPR synthetic lethality screens in PSIS models can identify biomarkers for early diagnosis or treatment response. For instance:

• • Genome-wide knockout screens in PROP1-mutant cells to find genes whose loss is lethal, indicating vulnerabilities.
• • Transcriptomic profiling of edited cells to identify differentially expressed genes as candidate biomarkers.
• • Validation of circulating biomarkers like miR-26b in patient samples.

These approaches accelerate biomarker development for rare diseases.